Sotagliflozin to Lower Proteinuria in Recipients of a Kidney Transplant (SPARK)

November 11, 2026 updated by: Finnian Mc Causland

Sotagliflozin to Lower ProteinuriA in Recipients of a Kidney Transplant (SPARK)

Determine the effect of sotagliflozin versus placebo on the reduction in albuminuria from baseline to end of treatment (~180 days) among adult patients with a stable kidney transplant.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

Multicenter, randomized, double-blind, placebo-controlled trial to demonstrate the superiority of sotagliflozin at a dose of 200 milligrams daily, compared with placebo, on the reduction of the urine albumin:creatinine ratio (UACR) among kidney transplant recipients (KTRs)

Study Type

Interventional

Enrollment (Estimated)

180

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male and female KTRs aged ≥18 years
  • >6 months post kidney transplantation
  • Urine albumin/creatinine ratio >100mg/g
  • eGFR between ≥25 and ≤90 mL/min/1.73 m2
  • Stable allograft function

Exclusion Criteria:

  • Signs or symptoms of volume depletion (including symptomatic hypotension <90 mmHg systolic blood pressure)
  • Recurrent urinary tract infections (>2 episodes/year or antibiotic prophylaxis)
  • Biopsy-proven acute rejection within 12 weeks
  • Uncontrolled hypertension (systolic blood pressure >180 or diastolic blood pressure >100 mmHg)
  • New York Heart Association (NYHA) Class IV heart failure
  • Myocardial infarction, unstable angina, revascularization procedure (e.g., stent or bypass graft surgery), or cerebrovascular accident within 12 weeks
  • History of diabetic ketoacidosis
  • Type 1 Diabetes Mellitus
  • Hereditary glucose-galactose malabsorption or primary renal glucosuria
  • Liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis); Alanine aminotransferase (ALT) levels >2.0 times the upper limit of normal (ULN) or total bilirubin >1.5 times the ULN, unless consistent with Gilbert's disease; moderate to severe hepatic impairment based on the Child-Pugh classification (class B or C)
  • Human immunodeficiency virus antibody positive
  • Major surgery within 12 weeks
  • Atraumatic amputation within past 12 months of screening, or an active skin ulcer, osteomyelitis, gangrene, or critical ischemia of the lower extremity within 6 months of screening
  • Combination use of ACEi and ARB
  • Current use of an SGLT2 inhibitor (within 12 weeks prior to randomization)
  • Known allergies, hypersensitivity, or intolerance to SGLT2i or its excipients
  • Digoxin use with plasma level >1.2 ng/mL
  • Clofibrate, fenofibrate, dronedarone, or ranolazine treatment that has not been at a stable dose in the 30 days prior to screening or randomization, or a dose adjustment is expected
  • Current use of rifampin
  • Received an active investigational drug (including vaccines) other than a placebo agent, or used an investigational medical device within 12 weeks before Day 1/baseline
  • Pregnant or breast-feeding or planning to become pregnant or breast-feed during the study
  • Women of childbearing potential* not willing to use a highly-effective method(s) of birth control, or who are unwilling or unable to be tested for pregnancy
  • Any condition that in the opinion of the investigator would make participation not in the best interest of the subject

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Sotagliflozin

Sotagliflozin at 200 mg daily via oral route for 180 days, followed by a 30 day off-drug period (total study time 210 days).

Eligible participants will be randomized in a 1:1 ratio to either sotagliflozin 200mg or matching placebo daily

Placebo Comparator: Placebo

Matching placebo once daily via oral route for 180 days, followed by a 30 day off-drug period (total study time 210 days).

Eligible participants will be randomized in a 1:1 ratio to either sotagliflozin 200mg or matching placebo daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in albuminuria from baseline to end of treatment (~180 days)
Time Frame: 180 days

Primary Efficacy Outcome

180 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
total slope of eGFR from baseline to end of follow-up (~30 days post-cessation of randomized therapy)
Time Frame: 210 days

Secondary Efficacy Outcome

210 days
Decline in UACR by 30% or greater from baseline to end of treatment (~180 days)
Time Frame: 210 days

Secondary Efficacy Outcome

210 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Finnian R Mc Causland, MBBCh, MMSc, Massachusetts General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2027

Primary Completion (Estimated)

March 1, 2029

Study Completion (Estimated)

September 1, 2029

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized data will be shared with collaborating institutions to facilitate a pre-specified pooled analysis.

IPD Sharing Time Frame

November 10, 2027 through 6 months after study closeout.

IPD Sharing Access Criteria

Anonymized data will be shared under completed data use agreements to facilitate pre-specified pooled analyses.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe